Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PGD | P52209 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19281218 | 1.00 | PGK1 (0.38) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL9952548 | 1.00 | PGK1 (0.38) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL27241907 | 0.97 | PGK1 (0.37) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL26913628 | 0.97 | PGK1 (0.37) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL23931184 | 0.95 | PGK1 (0.35) | PGK1PGK2LAP3TP53PGD | |
| SCHEMBL183389 | 0.79 | SMPD1 (0.34) | PGK1PGK2SMPD1TDP1 | |
| SCHEMBL8416620 | 0.78 | PEPD (0.43) | PGK1PGK2LAP3SMPD1KDM4E | |
| SCHEMBL11522192 | 0.77 | CA4 (0.40) | LAP3PGDSMPD1TDP1 | |
| Ammonia Solution, Strong SCHEMBL28328876 | 0.77 | SMPD1 (0.33) | PGK1PGK2SMPD1TDP1 | |
| SCHEMBL12257190 | 0.77 | LAP3 (0.44) | LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107075588-B | Methods and systems for microbiome-derived diagnosis and treatment | 普梭梅根公司 | 2023-03-21 | — | — | CN | claimed |
| CN-105136877-B | The preparation method of people's odor-binding protein sensor of nanohole array and application | 浙江大学 | 2018-06-22 | — | — | CN | claimed |
| CN-107334022-A | A kind of preparation method rich in the former wine drink of beta glucan | 李辉 | 2017-11-10 | — | — | CN | claimed |
| EP-2872514-B1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | claimed |
| US-9273057-B2 | Imidazotriazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | claimed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | claimed |
| EP-1019418-B1 | INOSITOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BIONERIS AB (SE) | 2004-04-28 | — | — | EP | claimed |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | NEURODERM LTD (IL) | 2025-03-13 | — | — | US | disclosed |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | NEURODERM, LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| WO-2023195753-A1 | BUILDING INTERIOR AND EXTERIOR COMPOSITE INSULATION MATERIAL WITH SEMI-NONCOMBUSTIBLE PERFORMANCE, EXCELLENT FLAME RETARDANCY AND MOISTURE PROOF PERFORMANCE, AND ENHANCED ENERGY EFFICIENCY | 삼우에스엔씨코 주식회사 | 2023-10-12 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| CN-107075588-B | Methods and systems for microbiome-derived diagnosis and treatment | 普梭梅根公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-1019418-A1 | A NEW CHEMICAL COMPOUND | PERSTORP AB (SE) | 2000-07-19 | — | — | EP | disclosed |
| EP-1012298-A1 | YEAST STRAINS FOR THE PRODUCTION OF LACTIC ACID | A.E. STALEY MANUFACTURING COMPANY (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999014335-A1 | YEAST STRAINS FOR THE PRODUCTION OF LACTIC ACID | A.E. STALEY MANUFACTURING COMPANY (US) | 1999-03-25 | — | — | WO | disclosed |
| EP-0857203-A2 | METHODS AND COMPOSITIONS TO IMPROVE GERM CELL AND EMBRYO SURVIVAL AND FUNCTION | Advanced Reproduction Technologies, Inc. (US) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997026266-A1 | A NEW CHEMICAL COMPOUND | PERSTORP AB (SE) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997014785-A2 | METHODS AND COMPOSITIONS TO IMPROVE GERM CELL AND EMBRYO SURVIVAL AND FUNCTION | ADVANCED REPRODUCTION TECHNOLOGIES, INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| EP-0192113-B1 | Cationic coating compositions for electrodeposition over rough steel | PPG INDUSTRIES INC (US) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | PGK1 3077/4885PGK2 2597/4885LAP3 94/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | PGK1 2114/4885PGK2 2042/4885LAP3 3152/4885 |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | DDC, DDT, COMT | PGK1 2958/4885PGK2 2512/4885LAP3 102/4885 |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | DDC, COMT, DDT | PGK1 3197/4885PGK2 2646/4885LAP3 163/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | PGK1 3059/4885PGK2 2577/4885LAP3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.